Safety and tolerability of intravenous ibandronate injections: DIVA 1-year analysis.

被引：0
|
作者：
Drezner, MK
Ste-Marie, LG
Nuti, R
Benhamou, C
Leigh, C
Ward, P
Masanauskaite, D
Lewiecki, EM
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] GRECC, Madison, WI USA
[3] CHUM Hop St Luc, Montreal, PQ, Canada
[4] Univ Siena, I-53100 Siena, Italy
[5] IPROS, CHR, Orleans, France
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2005年 / 20卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [1] Renal tolerability of ibandronate when administered by intravenous injection:: DIVA 1-year analysis.
    Civitelli, R
    Tankó, LB
    Vyskocil, V
    Leigh, C
    Ward, P
    Masanauskaite, D
    Recker, RR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S284 - S285
  • [2] Two-year safety and tolerability profile of intravenous ibandronate injections: The diva study
    Adami, S.
    Prince, R.
    Halse, J.
    Leigh, C.
    Masanauskaite, D.
    Jonkanski, I.
    Reid, D. M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [3] Renal safety of intravenous ibandronate injections in postmenopausal osteoporosis (PMO): DIVA 1-year results
    Civitelli, R
    Emkey, R
    Bolognese, M
    Recker, R
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 795 - 795
  • [4] Favourable renal safety and tolerability profile of intravenous ibandronate injections in women with postmenopausal osteoporosis: 1-year results from diva
    Reid, DM
    Felsenberg, D
    Christiansen, C
    Leigh, C
    Ward, P
    Sedarati, F
    Delmas, PD
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 365 - 365
  • [5] Intermittent intravenous ibandronate injections are at least as effective as daily oral ibandronate: 1-Year DIVA results
    Lewiecki, M
    Zaidi, M
    Drezner, M
    Recknor, C
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 802 - 802
  • [6] Favorable renal safety profile of intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from DIVA
    Delmas, P
    Reid, D
    Felsenberg, D
    Leigh, C
    Ward, P
    Sedarati, F
    Christiansen, C
    BONE, 2005, 36 : S419 - S420
  • [7] Efficacy of intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from DIVA.
    Bolognese, M
    Reid, DM
    Langdahl, B
    Hughes, C
    Ward, P
    Masanauskaite, D
    Olszynski, WP
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S96 - S96
  • [8] Incidence of influenza-like symptoms with intermittent intravenous ibandronate injections:: 1-year results from DIVA
    Reid, DM
    Tankó, LB
    Felsenberg, D
    Adami, S
    Leigh, C
    Ward, P
    Masanauskaite, D
    Delmas, PD
    BONE, 2005, 36 : S425 - S425
  • [9] Renal tolerability profile of intermittent intravenous ibandronate injections in postmenopausal women with osteoporosis: DIVA 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S125 - S125
  • [10] Favorable renal tolerability with intermittent intravenous ibandronate injections: The DIVA study.
    Civitelli, R.
    Stepan, J.
    Leigh, C.
    Ward, P.
    Burdeska, A.
    Reid, D. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S414 - S414
12345